摘要
目的:探讨老年弥漫大B细胞淋巴瘤(DLBCL)患者的临床特征及预后因素。方法回顾性分析2010年1月至2013年1月,第四军医大学西京医院血液内科收治的50例年龄≥70岁的老年DLBCL患者,收集整理年龄、Ann-Arbor分期、B症状、国际预后指数(IPI)、乳酸脱氢酶(LDH)、β2?微球蛋白、Ki-67等资料进而分析临床特点;采用Kaplan-Meier法进行生存分析,并进行单因素分析评估预后。结果50例初发老年DLBCL患者中,60%患者为Ⅲ~Ⅳ期,54% IPI评分为3~5分,52%有B症状,75%原发部位为结外。在老年患者中,调整剂量的化疗疗效优于放疗及对症支持治疗。利妥昔单抗联合剂量调整化疗(R-CHOP)组完全缓解(CR)率优于不包括利妥昔单抗的剂量调查化疗(CHOP/COP)组。患者中位生存时间为8个月,1、2、3年总生存率分别为48.5%、30.8%、11.5%。生存分析发现Ki-67对患者生存有显著的影响,尤其是Ki-67>80%患者预后差。结论老年患者以疾病分期晚,易合并其他系统疾病,生存期短为特征,具有更高的DLBCL发病率,Ki-67是一个重要的不良预后指标。R-CHOP方案可明显提高CR率,并且足够疗程的化疗将显著改善超高龄患者的生存期。
ObjectiveTo investigate the clinical characteristics and prognostic factors of diffuse large B-cell lymphoma (DLBCL) in theelderly.MethodsA total of50 DLBCL patients (≥70 years old) admittedin our department from Jan. 2010 to Jan. 2013 were enrolled in this study. Clinical data including age, Ann-Arbor stage, B symptoms,international prognostic index(IPI),serum levels of lactic dehydrogenase(LDH), β2-microglobulin(β2-MG) and Ki-67, and otherindices were collected andretrospectively analyzed. Survival analysis was performed by Kaplan-Meiersurvival analysis (the Log-rank test), and the correlationof theseindiceswith prognosis was performed by univariate analysis.Results Among the 50 elderly with initial DLBCL, 60% were at Ann-Arbor stage ofⅢ?Ⅳ, 54% got IPI score of 3?5 points, 52% had B symptoms, and 75% were with extranodal as primary site of the disease. Inthe cohort, the therapeutic effect was betterin the patients given dose-adjusted chemotherapy thanthose receiving radiotherapy and supportive therapy. Moreover, thecomplete remission(CR) rate was higherin the patients getting R-CHOPregimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednison) thanthoseof CHOP/COP regimens. The median survival time was 8 months, and the1-, 2-, 3-yearoverall survival rate (OS) was 48.5%, 30.8% and 11.5%, respectively. Survival analysis showed Ki-67 had great effect onprognosis, and those with Ki-67>80% had poor outcome.Conclusion Elderly patients are characterizedby being at late stage of disease,withvarious combined diseases,and havingshort survival time, and have a high incidence of DLBCL. Ki-67is regarded asan importantfactor forpoor prognosis.The R-CHOP schemegreatlyimproves CR rate, and adequate chemotherapy is important to prolong survival time intheelderly DLBCL patients.
出处
《中华老年多器官疾病杂志》
2015年第11期804-808,共5页
Chinese Journal of Multiple Organ Diseases in the Elderly
基金
国家自然科学基金(81360641)This work was supported bytheNational NaturalScience Foundation of China